Physician profile
Sam M Faradyan
NPI 1013076470
$1,830.22
in general payments reported to CMS, 2019-2025
13 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $124 · 2021: $64.45 · 2022: $41.29 · 2023: $280 · 2024: $319 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,026.64 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $806.84 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $314.65 | 2019-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $225.72 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $131.25 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $98.66 | 2021-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $55.04 | 2020-2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Boston Scientific Corporation | $45.28 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $38.25 | 2019 | |
| Resmed Corp | $37.95 | 2019-2020 | |
| Breas Medical, INC. | $23.27 | 2024 | Vivo 45 Ls |
| Gilead Sciences, INC. | $20.39 | 2021 | |
| Circassia INC. | $17.92 | 2019 | |
| Grifols USA, LLC | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Faradyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.